A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

Korábbi kezelés

• Patients diagnosed with concomitant indications for tofacitinib [psoriatic arthritis (PsA), UC, and polyarticular course juvenile idiopathic arthritis (pcJIA)] at any time prior to cohort entry date, determined by at least two (2) diagnosis codes at least 30 days apart and prior to baseline.

Egyéb

• Patients with >1 b/tsDMARD (ie, tofacitinib, etanercept, adalimumab, certolizumab, golimumab, infliximab, abatacept tocilizumab, or sarilumab) prescribed on index date.

• Age ≥18 years on the cohort entry date.
• Diagnosed with rheumatoid arthritis (RA) at any time prior to cohort entry date:
  • At least two RA diagnosis codes at least 30 days apart, each coming from an encounter with a rheumatologist;
  • At least one inpatient visit with a RA diagnosis code;
  • At least two outpatient records with a RA diagnosis code at least 30 days apart and within a year, regardless of physician specialty; or
  • At least one outpatient record with an RA diagnosis and a prescription or fill for a disease modifying anti-rheumatic drug (DMARD) from a specified list and does not have any of the non-RA conditions for which those drugs may also be prescribed.
• Initiation of specified biologic or targeted synthetic molecule DMARDs of interest for treatment of RA (ie, tofacitinib, etanercept, adalimumab, certolizumab, golimumab, infliximab, abatacept, tocilizumab, or sarilumab).
• At least 180 days of baseline data available prior to and including the cohort entry date.
• At least one Clinical Disease Activity Index (CDAI) score in 45 days prior to and including the cohort entry date (baseline).